Insider Selling: Revvity, Inc. (NYSE:RVTY) Insider Sells $412,510.00 in Stock

Revvity, Inc. (NYSE:RVTY) insider Joel S. Goldberg sold 3,500 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total value of $412,510.00. Following the completion of the sale, the insider now owns 33,400 shares in the company, valued at $3,936,524. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Revvity Price Performance

RVTY opened at $118.75 on Friday. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $128.15. The company has a 50 day moving average of $110.91 and a two-hundred day moving average of $107.45. The company has a market cap of $14.65 billion, a P/E ratio of 98.14, a P/E/G ratio of 2.97 and a beta of 1.05. The company has a quick ratio of 1.92, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The firm had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same period in the prior year, the company earned $1.21 EPS. The firm’s revenue was down 2.5% on a year-over-year basis. On average, analysts expect that Revvity, Inc. will post 4.75 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, October 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.24%. Revvity’s payout ratio is currently 23.14%.

Analyst Upgrades and Downgrades

RVTY has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Revvity from $105.00 to $120.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Robert W. Baird upped their price objective on shares of Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research note on Tuesday, April 30th. Barclays lifted their target price on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 30th. Jefferies Financial Group increased their price target on Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Finally, Citigroup lifted their price objective on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Revvity presently has a consensus rating of “Moderate Buy” and an average target price of $123.81.

Hedge Funds Weigh In On Revvity

A number of institutional investors and hedge funds have recently bought and sold shares of RVTY. Parkside Financial Bank & Trust purchased a new stake in shares of Revvity during the fourth quarter valued at approximately $25,000. Rothschild Investment LLC acquired a new stake in Revvity during the 2nd quarter valued at $25,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Revvity during the 4th quarter worth $27,000. CENTRAL TRUST Co acquired a new position in Revvity in the 4th quarter worth $27,000. Finally, ORG Partners LLC purchased a new position in Revvity in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.